This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Health Stocks in Motion

Updated from 3:42 p.m. EDT

Shares of Isis Pharmaceuticals (ISIS) were up 6.82% after the company announced that its phase I clinical trial of ISIS 301012, a cholesterol-reducing drug, produced rapid, dose-dependent and prolonged reductions of its target ApoB-100, while reducing LDL cholesterol and VLDL cholesterol levels.

The reductions occurred after one month of dosing and lasted more than 100 days. "ISIS 301012 is already showing the potential for an attractive profile, validating what we saw in preclinical studies, and we are excited about moving forward in clinical development," said Mark Wedal, vice president of clinical research and chief medical officer at Isis. The stock closed up 24 cents to $3.76.

Shares of Able Laboratories (ABRX) slid 7.39% after the company announced that it is making further staff reductions. The company did not specify how many workers it would be laying off. The company said the cuts would help "conserve assets and assist it in retaining key employees as it continues to address pending regulatory issues." Able previously suspended its manufacturing operations after discovering problems with them. The stock traded down 32 cents to $4.02.

Shares of Canadian health care provider MDS (MDZ) were up 0.21% after the company said it earned $30.24 million, or roughly 16 cents a share, for the second quarter ended April 30, compared with earnings of $51.73 million, or 19 cents, a year ago. Revenue for the quarter was $318.35 million, unchanged from a year ago. The stock traded up 13 cents to $14.38 after trading as low as $13.82 on the day.

CuraGen (CRGN) rose 6.82% after its majority owned subsidiary, 454 Life Sciences, reported that one of its scientists had detailed a potentially new application for the company's technology -- ultra-deep sequencing of the HIV virus. Identifying and understanding HIV drug resistance is necessary to ensure the appropriate use of antiretroviral drugs and to minimize the spread of resistance. The stock closed up 26 cents to $4.07.

Other health stocks on the move were Merck (MRK), down 28 cents to $31.35; Biogen Idec (BIIB), up $1.78 to $35.13; Elan (ELN), up 77 cents to $7.37; and Pfizer (PFE), down 12 cents to $27.53.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs